SPR-741, with the CAS number 1179330-52-9, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. It is classified as a selective modulator of the immune response, specifically targeting the immune checkpoint protein PD-1 (programmed cell death protein 1). This modulation can enhance T-cell activation and proliferation, making it a candidate for cancer immunotherapy. SPR-741 is characterized by its ability to influence immune pathways, potentially improving the efficacy of existing cancer treatments. Its chemical structure includes specific functional groups that contribute to its biological activity and selectivity. As research continues, the pharmacokinetics, safety profile, and overall effectiveness of SPR-741 are being evaluated in preclinical and clinical studies, aiming to establish its role in enhancing anti-tumor immunity and overcoming resistance to other forms of cancer therapy.

SPR-741

1179330-52-9: SPR-741, with the CAS number 1179330-52-9, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. It is classified as a selective modulator of the immune response, specifically targeting the immune checkpoint protein PD-1 (programmed cell death protein 1). This modulation can enhance T-cell activation and proliferation, making it a candidate for cancer immunotherapy. SPR-741 is characterized by its ability to influence immune pathways, potentially improving the efficacy of existing cancer treatments. Its chemical structure includes specific functional groups that contribute to its biological activity and selectivity. As research continues, the pharmacokinetics, safety profile, and overall effectiveness of SPR-741 are being evaluated in preclinical and clinical studies, aiming to establish its role in enhancing anti-tumor immunity and overcoming resistance to other forms of cancer therapy.

<p>SPR741, a cationic peptide from polymyxin B, is being developed to treat serious Gram-negative infections.</p>

SPR741

<p>SPR741 is an antimicrobial potentiator, which is derived from polymyxin B, an antibiotic sourced from the bacterium *Bacillus polymyxa*. Its mode of action involves permeabilizing the outer membrane of Gram-negative bacteria, allowing otherwise impermeable antibiotics to enter the bacterial cell. This potentiation effect significantly enhances the efficacy of co-administered antibiotics against resistant strains.</p>

CAS 1179330-52-9

SPR-741

SPR741

Ref: TM-TP1090

SPR741

Ref: 3D-EXB33052